Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Other Non-Current Assets (2016 - 2025)

Historic Other Non-Current Assets for Agios Pharmaceuticals (AGIO) over the last 14 years, with Q4 2025 value amounting to $3.9 million.

  • Agios Pharmaceuticals' Other Non-Current Assets fell 1678.66% to $3.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $3.9 million, marking a year-over-year decrease of 1678.66%. This contributed to the annual value of $3.9 million for FY2025, which is 1678.66% down from last year.
  • Agios Pharmaceuticals' Other Non-Current Assets amounted to $3.9 million in Q4 2025, which was down 1678.66% from $3.9 million recorded in Q3 2025.
  • In the past 5 years, Agios Pharmaceuticals' Other Non-Current Assets registered a high of $4.7 million during Q4 2024, and its lowest value of $2.9 million during Q2 2021.
  • For the 5-year period, Agios Pharmaceuticals' Other Non-Current Assets averaged around $3.8 million, with its median value being $4.0 million (2022).
  • The largest annual percentage gain for Agios Pharmaceuticals' Other Non-Current Assets in the last 5 years was 11481.48% (2021), contrasted with its biggest fall of 9394.05% (2021).
  • Quarter analysis of 5 years shows Agios Pharmaceuticals' Other Non-Current Assets stood at $2.9 million in 2021, then surged by 36.41% to $4.0 million in 2022, then rose by 2.55% to $4.1 million in 2023, then increased by 16.44% to $4.7 million in 2024, then fell by 16.79% to $3.9 million in 2025.
  • Its Other Non-Current Assets was $3.9 million in Q4 2025, compared to $3.9 million in Q3 2025 and $3.9 million in Q2 2025.